文献速递妇科

高危早期宫颈癌淋巴结转移术后放疗的人群趋势与结局:同步放化疗与单纯放疗比较

Populational trends and outcomes of postoperative radiotherapy for high-risk early-stage cervical cancer with lymph node metastasis: concurrent chemo-radiotherapy versus radiotherapy alone.
PubMed 文献 · Am J Obstet Gynecol · 2019-10-31

该研究基于1988至2016年SEER数据库,纳入2538例接受子宫切除及术后放疗的T1-2期宫颈癌伴盆腔淋巴结转移患者,比较同步放化疗(n=1809)与单纯放疗(n=729)的生存。倾向评分加权后,两组5年总生存率相似(73.1% vs 73.6%;HR 1.004;95%CI 0.887-1.136;P=0.955)。尽管同步化疗使用率显著上升,但人群水平5年总生存率未见变化。

要点

  • 同步放化疗使用率从1997-2000年的20.7%升至78.5%(P=0.052),至2016年达88.3%(P<0.001)。
  • 倾向评分加权后,同步放化疗组与单纯放疗组5年总生存率相似(73.1% vs 73.6%;HR 1.004;95%CI 0.887-1.136;P=0.955)。
  • 亚组分析中,老年、非鳞癌、T2期及多发淋巴结转移患者两组生存均无显著差异(均P>0.05)。

核心结论

  • 在早期宫颈癌伴淋巴结转移患者中,术后放疗期间同步化疗的使用与生存改善无关。

研究设计与样本

  • 基于SEER数据库1988至2016年的人群队列研究,纳入2538例接受子宫切除及术后放疗的T1-2期宫颈癌伴盆腔淋巴结转移患者。
  • 比较单纯放疗组(n=729)与同步放化疗组(n=1809),采用倾向评分逆概率治疗加权校正混杂因素。

主要发现

  • 同步化疗使用率从1997-2000年的20.7%升至78.5%(P=0.052),至2016年达88.3%(P<0.001)。
  • 多变量模型中,非鳞癌和近期诊断者更可能接受同步放化疗,老年女性更少接受(均P<0.05)。
  • 人群水平5年总生存率无变化(1997-2012年年度百分比变化-0.1;95%CI -1.2至1.0;P=0.776)。
  • 倾向评分加权队列中,同步放化疗组与单纯放疗组5年总生存率相似(73.1% vs 73.6%;HR 1.004;95%CI 0.887-1.136;P=0.955)。
  • 老年、非鳞癌、T2期及多发淋巴结转移亚组中两组生存均无显著差异(均P>0.05)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pelvic lymph node metastasis carries the highest impact on decreased survival among surgical-pathological risk factors for early-stage cervical cancer. Although concurrent administration of chemotherapy during postoperative radiotherapy is the current standard treatment for surgically treated high-risk early-stage cervical cancer, its effectiveness specific to node-positive disease has not been completely studied. OBJECTIVE: To examine the association between the use of concurrent chemotherapy and survival in women with early-stage cervical cancer and nodal metastasis receiving adjuvant radiotherapy. MATERIALS AND METHODS: This is a population-based cohort study using the Surveillance, Epidemiology, and End Results Program from 1988 to 2016. Women with stage T1-2 cervical cancer with pelvic lymph node metastasis who underwent hysterectomy and received postoperative radiotherapy were examined. Trends, characteristics, and overall survival were compared between women who received postoperative radiotherapy alone (n = 729) or in combination with concurrent chemo-radiotherapy (n = 1809). Propensity score-based inverse probability of treatment weighting was used to account for the effect of measured covariates on treatment selection. RESULTS: Among 2538 women, there was a marked increase in the use of concurrent chemotherapy from 1997 to 2000 (20.7% to 78.5%, P = .052), followed by a more gradual rise through 2016 (88.3%, P < .001). In a multivariable model, women with non-squamous cell carcinomas and those diagnosed more recently were more likely to receive concurrent chemo-radiotherapy, whereas older women were less likely to receive concurrent chemo-radiotherapy (all, P < .05). At the population level, the 5-year overall survival rates remained unchanged (annual percent change for 1997-2012: -0.1; 95% confidence interval, -1.2 to 1.0; P = .776). In a propensity score weighted cohort, women who received concurrent chemo-radiotherapy had a 5-year overall survival rate similar to women treated with radiotherapy alone (73.1% vs 73.6%; hazard ratio, 1.004; 95% confidence interval, 0.887-1.136; P = .955). Significant differences were also not seen in older women, nonsquamous types, stage T2 disease, and multiple node metastases (all, P > .05). CONCLUSION: Despite the marked increase in the use of concurrent chemo-radiotherapy for women with early-stage cervical cancer and nodal metastases, there was no association between use of concurrent chemotherapy during postoperative radiotherapy and improved survival.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Matsuo K, Nusbaum DJ, Machida H, et al. Populational trends and outcomes of postoperative radiotherapy for high-risk early-stage cervical cancer with lymph node metastasis: concurrent chemo-radiotherapy versus radiotherapy alone. Am J Obstet Gynecol. 2019. PMID: 31678092. doi:10.1016/j.ajog.2019.10.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。